Conditions: Non Small Cell Lung Cancer
Keywords: Untreated NSCLC in patients > 70
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 63
Healthy volunteers: no

Brief summary:
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Detailed description:
In this trial, the activity and tolerability of sunitinib malate (Sutent) will be examined in previously untreated elderly patients (\>70 years old) felt not to be candidates for standard cytotoxic chemotherapy.

Arms:
arm 1: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.

Interventions: intervention 1: Sutent
Intervention descriptions: intervention 1: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.

Protocol document: